. Author manuscript; available in PMC: 2015 Oct 1.

Published in final edited form as: Psychopharmacology (Berl). 2014 Mar 15;231(19):3899–3905. doi: 10.1007/s00213-014-3528-z

Table 1.

Demographics and methods by laboratory

	Sample size	Age (years)	Weight (kg)	MDMA use (lifetime)	MDMA dose (mg)	Blinding	Testing context	Time of Dosing
SF	N=45 (20 F, 25 M)	28.0±6.7^*^†	68.1±12.9	32.8±37.0^*^†	1.5mg/kg	MDMA or placebo	researchers present	11:00 am
Chicago	N=95 (37 F, 58 M)	24.3±4.5	69.9±11.1	13.1±13.5^†	1.5mg/kg	Stimulant, sedative, cannabinoid, placebo	participants alone	9:30 am
Basel	N=80 (40 F, 40 M)	25.4±5.2	68.1±11.4	0.6±0.6	1.89 ± 0.33 mg/kg	MDMA or placebo	researchers present	8–9:00 am

Note: Blinding refers to the information the participant is given about the range of possible drugs administered in each study

denotes significantly different than Chicago lab (p < 0.05)

^†

denotes significantly different than Basel lab (p < 0.05)